Week of December 6th 2021 | Vol. 10, Issue 48 |
|
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business
Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America
Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
|
|
Early in 2020, there was a massive pandemic-induced nosedive in merger and acquisitions deals in healthcare. But the industry rapidly rebounded, carrying the momentum from the latter half of 2020—which saw a flurry of deals—into 2021, which saw an accelerated pace of activity.
Looking at the first half of 2021, there were 872 reported healthcare M&A transactions that closed, up 15% from the 738 transactions during H2 2020, Baker Tilly reported.
"It doesn’t take a rocket scientist to see that we're in a healthy climate for M&A," Don McDaniel, CEO of Canton & Company and a healthcare economist, entrepreneur and advisory services leader. "I think this is, by most accounts, a benchmark year in terms of overall M&A. It doesn't matter which sector you focus on; I think we’re going to continue to see that, we won’t see a lessening of the appetite."
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
17 transactions totaling $892 million
Supplies, Equipment & Services
21 transactions totaling $169 million
Healthcare IT & Managed Care
8 transactions totaling $1,448
Healthcare Facilities & Distributors
11 transactions totaling $1,085
|
|
Pharma & Biotech
32 transactions totaling $1,499 million
Supplies, Equipment & Services
19 transactions totaling $265 million
Healthcare IT & Managed Care
13 transactions totaling $295 million
Healthcare Facilities & Distributors
2 transactions totaling $50 million
|
|
Pharma & Biotech
9 transactions totaling $1,346 million
Supplies, Equipment & Services
3 transactions totaling $1,193
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
November 29, 2021 - Fierce Biotech
Blueprint Medicines knows a thing or two about lung cancer, with one approved medicine already in the bag through a partnership with Roche. Now, the biopharma is making a $250 million play to add another candidate with the acquisition of Lengo Therapeutics.
November 30, 2021 - Fierce Biotech
After merging its way onto the Nasdaq last year, kidney disease biotech Chinook Therapeutics is launching a new joint venture in the form of startup SanReno Therapeutics to deepen its footprint in China.
December 1, 2021 - Fierce Biotech
After performing its first laparoscopic procedure earlier this year with its miniaturized surgery robot, Virtual Incision has gathered $46 million in new funding to help complete clinical testing and begin the system’s commercial launch.
December 2, 2021 - Fierce Biotech
Tune Therapeutics wants in on the rising epigenomic field, spotlighted last month by Chroma Medicine's $125 million launch. Now, Tune has emerged with $40 million for its own epigenomic controls.
|
|
Events Hosted or Attended by Bourne Partners
Dates TBD - Charlotte, NC
January 10-14, 2022 - San Francisco, CA
|
|
|
|
Complete with additional workspaces, meeting spaces and staff lounge—this expansion will allow us to better accommodate our growing team as we continue to move forward with our hybrid work model.
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
